Non-invasive refractive treatment using nanoparticles
View Patent ↗Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye.
1. A method for optical treatment, the method comprising:
identifying an optical aberration of an eye,
determining a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye wherein the correction identifies changes to the index of refraction in the cornea of the eye; and
wherein the dopant comprises a plurality of nanoparticles.
2. The method of claim 1 , further comprising calculating the doping delivery device configuration in response to the optical aberration of the eye, the optical aberration of the eye comprising a high-order optical aberration, and wherein calculating the doping delivery device configuration comprises a location and concentration for dopant application to the eye.
3. The method of claim 1 , wherein the optical aberration of the eye comprises one of a myopia, a hyperopia, and a regular astigmatism.
4. The method of claim 1 , wherein the optical aberration of the eye comprises a higher order aberration.
5. The method of claim 1 , wherein configuring the dopant delivery device comprises activating dopant located on first portions of a contact lens.
6. The method of claim 5 , wherein dopant located on second portions of the contact lens is not activated.
7. The method of claim 6 , wherein the contact lens comprises an orienting feature configured to orient the contact lens on the eye.
8. The method of claim 5 , wherein the dopant is activated by the selective irradiation of the first portions of the dopant delivery device.
9. The method of claim 5 , wherein the dopant located on portions of the contact lens is configured to diffuse into the cornea.
10. The method of claim 5 , wherein the dopant is configured to implant in the corneal stroma.
11. A method of providing non-invasive optical correction to an eye comprising:
identifying the optical aberration of the eye;
calculating a corrective change to the index of refraction of the eye, wherein the change in the index of refraction compensates for the identified optical aberration of the eye;
calculating a doping pattern configured to compensate for the optical aberration of the eye, wherein the doping pattern comprises a description of the location and concentration for dopant application to the eye;
configuring a dopant delivery system;
delivering dopant to the eye according to the calculated doping pattern,
wherein the dopant is configured to implant in the corneal stroma, and wherein the dopant comprises a plurality of nanoparticles.
12. The method of claim 11 , wherein the doping pattern is calculated from the corrective change to the index of refraction of the eye.
13. The method of claim 11 , wherein the dopant delivery system comprises a contact lens carrying dopant.
14. The method of claim 11 , wherein configuring the dopant delivery system comprises applying dopant to portions of the contact lens identified by the doping pattern.
15. The method of claim 11 , wherein configuring the dopant delivery device comprises activating dopant located on first portions of a contact lens.
16. The method of claim 15 , wherein dopant located on second portions of the contact lens is not activated.
17. The method of claim 16 , wherein the contact lens comprises an orienting feature configured to orient the contact lens on the eye.
18. The method of claim 15 , wherein the dopant is activated by the selective irradiation of the first portions of the dopant delivery device.
19. The method of claim 15 , wherein the dopant located on portions of the contact lens is configured to diffuse into the cornea.